|
ALPS-AMI
Assessment of Lipophilic vs hydrophilic Statin therapy in Acute Myocardial Infarction
Ongoing trial
 |
Author(s) |
Kashima Y, Izawa A, Aizawa K, Koshikawa M, Kasai H, Tomita T, Kumazaki S, Tsutsui H, Koyama J, Ikeda U |
 |
Title(s) |
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study |
|
Reference(s) |
J Cardiol 2009;54:76–9 |
|
Disease |
AMI |
|
Purpose |
To compare the efficacy of atorvastatin vs pravastatin in the secondary prevention of cardiovascular events after AMI |
|
Study design |
Randomised, open, blinded endpoint |
|
Follow-up |
Aim 2 years |
|
Patients |
Aim 500 patients, aged > 18 years, with recent (< 4 days) PCI for ST-segment or non-ST-segment elevation MI |
|
Treatment regimen |
Atorvastatin, 10–20 mg/day, or pravastatin, 10–20 mg/day, to target LDL cholesterol < 100 mg/dl. Ezetimibe, 10 mg/day, added after 4 weeks if target LDL cholesterol not achieved |
|
Results |
Not yet available |
|
|
|
